Literature DB >> 28151833

Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain.

Hiroshi Ueda1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28151833     DOI： 10.1097/j.pain.0000000000000813

Source DB:  PubMed          Journal:  Pain        ISSN： 0304-3959            Impact factor:   6.961


× No keyword cloud information.
  14 in total

1.  A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration.

Authors:  Inés González-Gil; Debora Zian; Henar Vázquez-Villa; Gloria Hernández-Torres; R Fernando Martínez; Nora Khiar-Fernández; Richard Rivera; Yasuyuki Kihara; Isabel Devesa; Sakthikumar Mathivanan; Cristina Rosell Del Valle; Emma Zambrana-Infantes; María Puigdomenech; Giovanni Cincilla; Melchor Sanchez-Martinez; Fernando Rodríguez de Fonseca; Antonio V Ferrer-Montiel; Jerold Chun; Rubén López-Vales; María L López-Rodríguez; Silvia Ortega-Gutiérrez
Journal:  J Med Chem       Date:  2019-12-16       Impact factor: 7.446

2.  LPA1 receptor involvement in fibromyalgia-like pain induced by intermittent psychological stress, empathy.

Authors:  Hiroshi Ueda; Hiroyuki Neyama
Journal:  Neurobiol Pain       Date:  2017-04-17

3.  LPA1 , LPA2 , LPA4 , and LPA6 receptor expression during mouse brain development.

Authors:  Olga Suckau; Isabel Gross; Sandra Schrötter; Fan Yang; Jiankai Luo; Andreas Wree; Jerold Chun; David Baska; Jan Baumgart; Kuniyuki Kano; Junken Aoki; Anja U Bräuer
Journal:  Dev Dyn       Date:  2019-03-27       Impact factor: 3.780

4.  Lysophosphatidic acid LPA1 and LPA3 receptors play roles in the maintenance of late tissue plasminogen activator-induced central poststroke pain in mice.

Authors:  Hiroshi Ueda; Hiroyuki Neyama; Keita Sasaki; Chiho Miyama; Ryusei Iwamoto
Journal:  Neurobiol Pain       Date:  2018-07-20

5.  Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study.

Authors:  Ken Kuwajima; Masahiko Sumitani; Makoto Kurano; Kuniyuki Kano; Masako Nishikawa; Baasanjav Uranbileg; Rikuhei Tsuchida; Toru Ogata; Junken Aoki; Yutaka Yatomi; Yoshitsugu Yamada
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

6.  Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis.

Authors:  Kentaro Hayakawa; Makoto Kurano; Junichi Ohya; Takeshi Oichi; Kuniyuki Kano; Masako Nishikawa; Baasanjav Uranbileg; Ken Kuwajima; Masahiko Sumitani; Sakae Tanaka; Junken Aoki; Yutaka Yatomi; Hirotaka Chikuda
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

7.  CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia.

Authors:  Anne-Li Lind; David Just; Maria Mikus; Claudia Fredolini; Marina Ioannou; Björn Gerdle; Bijar Ghafouri; Emmanuel Bäckryd; Lars Tanum; Torsten Gordh; Anna Månberg
Journal:  J Pain Res       Date:  2019-10-15       Impact factor: 3.133

8.  MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia.

Authors:  Ioanna Plastira; Eva Bernhart; Lisha Joshi; Chintan N Koyani; Heimo Strohmaier; Helga Reicher; Ernst Malle; Wolfgang Sattler
Journal:  J Neuroinflammation       Date:  2020-04-23       Impact factor: 8.322

9.  Conditional Lpar1 gene targeting identifies cell types mediating neuropathic pain.

Authors:  Richard R Rivera; Mu-En Lin; Emily C Bornhop; Jerold Chun
Journal:  FASEB J       Date:  2020-06-17       Impact factor: 5.191

10.  Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model.

Authors:  Baasanjav Uranbileg; Nobuko Ito; Makoto Kurano; Daisuke Saigusa; Ritsumi Saito; Akira Uruno; Kuniyuki Kano; Hitoshi Ikeda; Yoshitsugu Yamada; Masahiko Sumitani; Miho Sekiguchi; Junken Aoki; Yutaka Yatomi
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.